If demand stabilizes, cost savings stick, and digital/aligners re-accelerate, XRAY could re-rate sharply
Dentsply Sirona (XRAY) has been treated like a “show-me” story: uneven procedure demand, choppy equipment cycles, and execution noise have kept investors cautious. But the ingredients for a meaningful re-rating are visible if 2026 delivers a steadier dental backdrop and management converts restructuring into durable earnings power.
The bull case starts with the macro. Analysts covering the dental supply chain have been looking for stabilization after a volatile 2025, with demand improving but still sensitive to consumer budgets—especially for higher-ticket procedures. If the industry simply moves from “stop-start” to “steady,” Dentsply’s mix of consumables, equipment, and digital workflow could see revenue trends inflect from declines toward low-single-digit growth.
Second is self-help. Dentsply’s multi-year transformation program targets meaningful annual cost savings (the company has cited an $80–$100 million run-rate savings opportunity tied to its plan). In a bull scenario, those savings don’t just offset inflation—they expand margins as volumes normalize, lifting operating leverage and free cash flow.
Third is product-led upside in faster-growing categories. Clear aligners remain a competitive battlefield, but Dentsply’s SureSmile platform gives it exposure to an orthodontics growth vector without being a single-product company. Pair that with continued digital dentistry adoption—integrated imaging, workflow software, and clinic connectivity—and Dentsply can improve “stickiness” while capturing a larger share of procedure economics.
So how does XRAY get to $45? At today’s price (~$13.5), the market is pricing in skepticism. A realistic bull framework is: (1) revenue stabilizes and returns to modest growth, (2) restructuring savings drive sustained margin expansion, and (3) EPS power normalizes to roughly $2.25–$2.75 over the next couple of years. Apply a mid-cycle multiple of ~16–20x—reasonable for a higher-quality, cash-generative dental franchise in recovery—and you arrive at $36–$55, with $45 as a clean midpoint.
Key catalysts would be consecutive quarters of improving organic trends, clear evidence that cost savings are permanent, and clearer signs that SureSmile/digital are gaining traction. The risk, of course, is that dental demand stays fragile and the cycle never cooperates—but if 2026 is the “steady” year the sector needs, XRAY’s upside could be far larger than the market currently discounts.
You might like this article:Reddit Enters a New Growth Era as Profits Surge and Share Buyback Signals Confidence
